A Committee of the United States Senate on Wednesday (March 6) passed the Biological Safety Act proposed by the US Senate, which was listed as one of the "one of the biotechnology companies that pay attention" on Thursday (March 7).The issuance statement said that the company strongly opposed the pre -definition and unfair definition of unreasonable procedures, and will continue to communicate and dialogue with the relevant parties in the draft and the corresponding bill legislative process of the US House of Representatives.change.
Comprehensive Surging News and Securities Times reported that Pharmaceutical Company, headquartered in Shanghai, said in a statement that the company did not constitute national security in the United States or in the United States or in the future in the past, and the futurerisk.The statement reiterates that the company has neither human genomic business, and there are various types of businesses nor collecting human genome data.
Yaoming Kant also said that in the next few months, the above draft will continue to experience the legislative process in the Senate.The company will cooperate with the consultant to communicate and dialogue with the relevant parties of the draft and the corresponding bill legislative processes participating in the United States House of Representatives. The content of the draft needs to be further reviewed and may be changed.
The US Senate Land and Safety Committee held a proposal hearing on Wednesday. The Biological Safety Act of the US Senate version was passed at the conference with 11-1 votes.
The cross -party group consisting of members of the two houses of the United States Power House proposed a draft version of the Biological Safety Act on January 25 this year. It is recommended to restrict the US administrative organs with several biotechnology suppliers.National security constituted risks, including Yaoming Kant and Yaoming creatures.
Yaoming Kant announced at the time that the US members' claims to threaten the company's national security constitution, and said that the company's "no past, present, and the future will not constitute national security risks to the United States". "Essence
Yaoming Kangde said in a announcement of the Hong Kong Stock Exchange on the 13th that the company has successfully passed the review of the US government many times in the past and has always welcomed supervision.risk.
After passing the Senate's version of the Biological Safety Act, the Yaoming Department fell sharply on Thursday.A -share medicine Ming Kangde's limit, Hong Kong stock Yaomingde fell more than 15%, and Yaoming creatures fell more than 20%.
